

# Archived Document

This archived document is no longer being reviewed through the CLSI Consensus Document Development Process. However, this document is technically valid as of August 2020. Because of its value to the laboratory community, it is being retained in CLSI's library.



August 2005

---

## H54-A

### Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline

This document describes the use of certified plasmas to enhance performance of the prothrombin time (PT)/International Normalized Ratio (INR) system test; reviews limitations of the INR system that may occur when a manufacturer-determined ISI is used without local verification or calibration; and provides a rationale for performing local ISI verification with recommendations as to when PT calibration may be indicated. Part I is a detailed, expanded account for manufacturers and Part II is an abbreviated version useful for the clinical laboratory.

---

A guideline for global application developed through the Clinical and Laboratory Standards Institute consensus process.

# Clinical and Laboratory Standards Institute

*Setting the standard for quality in medical laboratory testing around the world.*

The Clinical and Laboratory Standards Institute (CLSI) is a not-for-profit membership organization that brings together the varied perspectives and expertise of the worldwide laboratory community for the advancement of a common cause: to foster excellence in laboratory medicine by developing and implementing medical laboratory standards and guidelines that help laboratories fulfill their responsibilities with efficiency, effectiveness, and global applicability.

## Consensus Process

Consensus—the substantial agreement by materially affected, competent, and interested parties—is core to the development of all CLSI documents. It does not always connote unanimous agreement but does mean that the participants in the development of a consensus document have considered and resolved all relevant objections and accept the resulting agreement.

## Commenting on Documents

CLSI documents undergo periodic evaluation and modification to keep pace with advances in technologies, procedures, methods, and protocols affecting the laboratory or health care.

CLSI's consensus process depends on experts who volunteer to serve as contributing authors and/or as participants in the reviewing and commenting process. At the end of each comment period, the committee that developed the document is obligated to review all comments, respond in writing to all substantive comments, and revise the draft document as appropriate.

Comments on published CLSI documents are equally essential and may be submitted by anyone, at any time, on any document. All comments are managed according to the consensus process by a committee of experts.

## Appeal Process

When it is believed that an objection has not been adequately considered and responded to, the process for appeal, documented in the CLSI *Standards Development Policies and Processes*, is followed.

All comments and responses submitted on draft and published documents are retained on file at CLSI and are available upon request.

## Get Involved—Volunteer!

Do you use CLSI documents in your workplace? Do you see room for improvement? Would you like to get involved in the revision process? Or maybe you see a need to develop a new document for an emerging technology? CLSI wants to hear from you. We are always looking for volunteers. By donating your time and talents to improve the standards that affect your own work, you will play an active role in improving public health across the globe.

For additional information on committee participation or to submit comments, contact CLSI.

Clinical and Laboratory Standards Institute

P: +1.610.688.0100

F: +1.610.688.0700

[www.clsi.org](http://www.clsi.org)

[standard@clsi.org](mailto:standard@clsi.org)

ISBN 1-56238-580-1  
ISSN 0273-3099

H54-A  
Vol. 25 No. 23  
Replaces H54-P  
Vol. 24 No. 30

---

## Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline

Volume 25 Number 23

Dorothy M. Adcock, MD  
William F. Brien, MD, FRCP(C)  
Stephen L. Duff, MBA  
Marilyn Johnston, ART  
Stephen Kitchen, FIBMS, PhD

Richard A. Marlar, PhD  
Valerie L. Ng, PhD, MD  
Ton van den Besselaar, PhD  
Barry J. Woodhams, PhD

### Abstract

Clinical and Laboratory Standards Institute document H54-A—*Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline* is one in a series of guidelines that addresses methodology in blood coagulation testing. It is intended to provide guidance for both manufacturers and clinical laboratory personnel responsible for reporting patient INR results. H54 describes the use of certified plasmas to enhance performance of the prothrombin time (PT)/International Normalized Ratio (INR) system test; reviews limitations of the PT/INR system that may occur when a manufacturer-determined ISI is used without local verification or calibration; and provides a rationale for performing local ISI verification with recommendations as to when PT calibration may be indicated. This guideline is published in two parts. Part I provides an expanded account of the subject and Part II is an abbreviated version that may be useful in the clinical laboratory. Methods of calculating local ISI are provided and the procedure for creating a calibration line for direct INR determination is included. In the expanded guideline, the method of certified plasma preparation and method of INR value assignments are also described in detail. This guideline includes a recommended INR range that certified plasmas should cover and recommended number of certified plasmas required for local ISI calibration. A protocol for performing calibration of PT systems is provided. The objective of this guideline is to improve precision and trueness (accuracy) of PT/INR systems and enhance both laboratory standardization and patient care.

Clinical and Laboratory Standards Institute (CLSI). *Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline*. CLSI document H54-A (ISBN 1-56238-580-1). Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087 USA, 2005.

The Clinical and Laboratory Standards Institute consensus process, which is the mechanism for moving a document through two or more levels of review by the health care community, is an ongoing process. Users should expect revised editions of any given document. Because rapid changes in technology may affect the procedures, methods, and protocols in a standard or guideline, users should replace outdated editions with the current editions of CLSI documents. Current editions are listed in the CLSI catalog and posted on our website at [www.clsi.org](http://www.clsi.org). If your organization is not a member and would like to become one, and to request a copy of the catalog, contact us at: Telephone: 610.688.0100; Fax: 610.688.0700; E-Mail: [customerservice@clsi.org](mailto:customerservice@clsi.org); Website: [www.clsi.org](http://www.clsi.org).



DIN/NAMed

Copyright ©2005 Clinical and Laboratory Standards Institute. Except as stated below, any reproduction of content from a CLSI copyrighted standard, guideline, companion product, or other material requires express written consent from CLSI. All rights reserved. Interested parties may send permission requests to [permissions@clsi.org](mailto:permissions@clsi.org).

CLSI hereby grants permission to each individual member or purchaser to make a single reproduction of this publication for use in its laboratory procedure manual at a single site. To request permission to use this publication in any other manner, e-mail [permissions@clsi.org](mailto:permissions@clsi.org).

### **Suggested Citation**

CLSI. *Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline*. CLSI document H54-A. Wayne, PA: Clinical and Laboratory Standards Institute; 2005.

### **Previous Edition:**

October 2004

### **Reaffirmed:**

September 2016

### **Archived:**

August 2020

## Committee Membership

### Area Committee on Hematology

**Bruce H. Davis, MD**

**Chairholder**

**Maine Medical Center Research**

**Institute**

**Scarborough, Maine**

**Samuel J. Machin, MB, ChB, FRCPath**

**Vice-Chairholder**

**The University College London**

**Hospitals**

**London, United Kingdom**

Dorothy M. Adcock, MD

Esoterix Coagulation

Aurora, Colorado

Frank M. LaDuca, PhD

International Technidyne Corporation

Edison, New Jersey

Ginette Y. Michaud, MD

FDA Center for Devices and Radiological  
Health

Rockville, Maryland

Albert Rabinovitch, MD, PhD

Abbott Laboratories, Hematology

Business Unit

Santa Clara, California

Maryalice Stetler-Stevenson, MD,

PhD

National Institutes of Health

Bethesda, Maryland

#### Advisors

Charles F. Arkin, MD

Lahey Clinic

Burlington, Massachusetts

J. David Bessman, MD

University of Texas Medical Branch

Galveston, Texas

Sheila Clover, CPT(ASCP)(NCA)

Phlebotomy West

Brentwood, California

Dennis J. Ernst, MT(ASCP)

Center for Phlebotomy Education

Ramsey, Indiana

John A. Koepke, MD

Durham, North Carolina

Francis Lacombe, MD, PhD

Hôpital Haut-Lévêque

Pessac, France

Kandice Kottke Marchant, MD,

PhD

The Cleveland Clinic Foundation

Cleveland, Ohio

Richard A. Marlar, PhD

Oklahoma City VA Medical Center

Oklahoma City, Oklahoma

Diane I. Szamosi, MA,

MT(ASCP)SH

Greiner Bio-One

North America Preanalytics

Monroe, North Carolina

### Subcommittee on Calibration Plasmas

**Dorothy M. Adcock, MD**

**Chairholder**

**Esoterix Coagulation**

**Aurora, Colorado**

William F. Brien, MD, FRCP(C)

Princess Margaret Hospital

Toronto, Ontario, Canada

Stephen L. Duff, MBA

Precision BioLogic

Dartmouth, Nova Scotia, Canada

Marilyn Johnston, ART

Hemostasis Reference Laboratory

Hamilton, Ontario, Canada

Stephen Kitchen, FIBMS, PhD

Royal Hallamshire Hospital

Sheffield, United Kingdom

Richard A. Marlar, PhD

Oklahoma City VA Medical Center

Oklahoma City, Oklahoma

Valerie L. Ng, PhD, MD

San Francisco General Hospital

San Francisco, California

Ton van den Besselaar, PhD

Leiden University Medical Center

Leiden, The Netherlands

Barry J. Woodhams, PhD

Stago R&D

Gennevilliers, France

#### Advisors

John D. Olson, MD, PhD

University of TX Health Center

San Antonio, Texas

Norbert F. Zander, PhD

Dade Behring

Marburg, Germany

#### Staff

Clinical and Laboratory Standards

Institute

Wayne, Pennsylvania

John J. Zlockie, MBA

*Vice President, Standards*

David E. Sterry, MT(ASCP)

*Staff Liaison*

Patrice E. Polgar

*Projects Coordinator*

Donna M. Wilhelm

*Editor*

Melissa A. Lewis

*Assistant Editor*

## Contents

Abstract.....	i
Committee Membership.....	iii
Foreword.....	vii
1 Scope.....	1
2 Standard Precautions.....	1
3 Definitions .....	1
Part I. Detailed Version.....	5
4 Laboratory Monitoring of AVK Therapy .....	5
4.1 Recommended Method .....	5
4.2 Limitations of the INR System .....	6
4.3 Optimizing Current PT/INR Test Systems (Prior to Local Verification or Calibration) .....	11
5 Recommendations for Verification of the PT/INR Test System .....	11
5.1 Verification of INR Results .....	11
6 Recommendations for Further Improvement of the PT/INR Test System (INR Calibration) .....	13
6.1 PT/INR Calibration.....	13
6.2 General Guidelines for the Use of Certified Plasmas .....	13
6.3 Frequency of Calibration .....	14
6.4 Tissue Factor Species Effects .....	15
7 PT/INR System Calibration to Determine Local ISI .....	15
7.1 Procedure for Local ISI (ISI <sub>LS</sub> Determination) .....	16
7.2 Number of Certified Plasmas Required for Local ISI Calibration.....	16
7.3 Local System Verification Following ISI Calibration .....	16
7.4 Criteria for Acceptance of Locally Calculated ISI.....	17
7.5 Interpretation of Patient Test Results.....	17
8 PT/INR System Calibration to Determine Direct INR .....	17
8.1 Recommended Number and Preparation of Certified Plasmas.....	17
8.2 Procedure for Preparation of a Direct INR Calibration Line .....	18
8.3 Interferences.....	18
8.4 Guidelines for Determining Result Acceptance.....	18
8.5 Interpretation of Patient Test Results.....	19
9 Choice of Verification/Calibration Material .....	19
9.1 Method of Preparation of Certified Reference Materials.....	20
9.2 Validation of Certified Plasmas .....	23
9.3 Documentation Required by Manufacturers .....	23

**Contents (Continued)**

Part II. Abbreviated Version for Laboratorians .....	25
10 Introduction.....	25
10.1 Limitations of the INR System .....	26
10.2 ISI Value Assigned by the Manufacturer.....	26
10.3 Thromboplastin/Instrument Interaction .....	26
10.4 Components of INR Determination.....	27
11 Optimizing the Local PT/INR Test System .....	27
11.1 Prothrombin Time.....	27
11.2 Mean Normal Prothrombin Time.....	27
11.3 Thromboplastin Reagent With a Generic ISI.....	28
11.4 Thromboplastin Reagent With an Instrument/Reagent-Specific ISI .....	28
11.5 Use of Good Laboratory Practices.....	28
12 Recommendations for Verification of the Local Test System.....	28
12.1 Verification of INR Results .....	28
13 Local System Calibration.....	30
13.1 General Guidelines for the Use of Certified Plasmas .....	30
13.2 Procedure for Calculating Local ISI .....	30
13.3 Procedure for Establishing Direct INR (Locally) .....	32
13.4 Interpretation of Patient Test Results.....	33
References.....	34
Appendix A. Determination of the Geometric Mean Normal Prothrombin Time (MNPT) .....	37
Appendix B. Calculations for Local ISI Determination and Direct INR Calibration Line.....	38
Appendix C. INR Verification, ISI Calibration, and Direct INR Calibration Line Preparation Using Certified Plasmas.....	42
Summary of Consensus/Delegate Comments and Subcommittee Responses .....	43
The Quality System Approach.....	50
Related CLSI/NCCLS Publications.....	51

## Foreword

The prothrombin time (PT) is the most widely performed coagulation assay. It is commonly used to monitor antivitamin K therapy (AVK). The wide use of the PT has resulted in the introduction of numerous thromboplastin reagents and coagulation instruments. Thromboplastin reagents can vary widely in their response to AVK therapy depending on the source material from which they are derived. This can result in a wide range of PT results on identical patient plasmas. Patient samples have shorter clotting times when less responsive PT reagents are used and longer clotting times when a more responsive reagent is used. A wide assortment of instruments is available to measure PT assays using a number of different technologies for endpoint detection (e.g., optical-based or mechanical clot detection). PT test results may vary depending on the clot detection mechanism employed and brand of coagulation analyzer used. Variation in both thromboplastin reagent and instrumentation has contributed to a lack of standardization in PT test results.

In 1983, the World Health Organization (WHO) introduced the International Normalized Ratio (INR) for PT reporting in an effort to offset variation in thromboplastin reagent responsiveness and enhance standardization. An International Sensitivity Index (ISI) is assigned to each commercial lot number of thromboplastin reagent. The ISI is a measure of a reagent's responsiveness to depressed functional levels of vitamin K-dependent coagulation factors compared to the primary WHO International Reference Preparation (IRP). The INR is a mathematical conversion of the PT calculated as follows:

$$\text{INR} = (\text{Plasma PT} \div \text{MNPT})^{\text{ISI}}$$

Though the INR system has improved PT reporting, it is still associated with unexpectedly high degrees of inconsistency in values between laboratories and significant variation in locally reported INRs, compared to expected or true results. Such variation may negatively impact patient care as inaccuracies in INR determination can result in chronic over- or under-anticoagulation, resulting in increased patient morbidity and mortality.

Causes for variation in INR include, but are not limited to: 1) incorrect determination of the mean normal prothrombin time (MNPT) or PT; 2) difference in sodium citrate concentration employed for ISI determination compared to that used locally; 3) local effect of the reagent/instrument combination on the manufacturer's assigned ISI; 4) incorrect ISI value applied locally; 5) incorrect choice of IRP for reagent calibration, causing an inaccurate ISI value; and 6) inaccuracy and imprecision in the calibration of the commercial reagent against the appropriate IRP, causing an inaccurate and imprecise ISI value.

In order to optimize performance of the PT, it is recommended that a thromboplastin with an assigned ISI value specific for the laboratory's thromboplastin/instrument combination be used. This is in preference to a thromboplastin lacking an instrument-specific ISI (generic ISI [see the Definitions section]). When using a reagent with a thromboplastin/instrument-specific ISI, local ISI verification should be performed to ensure the ISI value is correct for the laboratory. If different, local calibration should be performed. When using a generic ISI, local verification is mandatory and local ISI calibration is strongly recommended.

Local PT calibration has been demonstrated to enhance the trueness (accuracy) and interlaboratory precision of INR determination. Local application of a conventional WHO calibration methodology is not feasible, as it is a labor-intensive, costly procedure using the manual tilt-tube method, and there is insufficient IRP available for individual laboratories. Instead, certified plasma samples with assigned PT/INR values can be used in individual laboratories to validate and if needed, calibrate the local instrument/reagent system. Local calibration can be achieved using certified plasmas by either calculating an ISI locally using orthogonal regression or by generating a calibration line upon which INR values are interpolated, a direct INR.

With the use of certified plasmas for INR verification and/or calibration of the local PT/INR systems, it is anticipated that clinical laboratories will not only report more accurate INRs, but also enhance laboratory to laboratory consistency, leading to improvements in monitoring antivitamin K therapy and, ultimately, patient outcomes.

### ***A Note on Terminology***

Clinical and Laboratory Standards Institute (CLSI), as a global leader in standardization, is firmly committed to achieving global harmonization wherever possible. Harmonization is a process of recognizing, understanding, and explaining differences while taking steps to achieve worldwide uniformity. CLSI recognizes that medical conventions in the global metrological community have evolved differently in the United States, Europe, and elsewhere; that these differences are reflected in CLSI, ISO, and CEN documents; and that legally required use of terms, regional usage, and different consensus timelines are all obstacles to harmonization. Despite these obstacles, CLSI recognizes that harmonization of terms facilitates the global application of standards and is an area that needs immediate attention. Implementation of this policy must be an evolutionary and educational process that begins with new projects and revisions of existing documents.

In keeping with CLSI's commitment to align terminology with that of ISO, the following describes the metrological terms and their uses in H54-A:

The term *accuracy* refers to the “closeness of the agreement between the result of a (single) measurement and a true value of a measurand” and comprises both random and systematic effects. *Trueness* is used in this document when referring to the “closeness of the agreement between the average value from a large series of measurements and to a true value of a measurand.” *Precision* is defined as the “closeness of agreement between independent test/measurement results obtained under stipulated conditions.” As such, it cannot have a numerical value, but may be determined qualitatively as high, medium, or low. For its numerical expression, the term *imprecision* is used, which is the “dispersion of results of measurements obtained under specified conditions.” In addition, different components of precision are defined in H54-A, primarily *repeatability* (i.e., “the closeness of the agreement between results of successive measurements of the same measurand carried out under the same conditions of measurement”); while *reproducibility* describes the “closeness of agreement of results of measurements under changed conditions.” The CLSI Harmonization Policy recognizes ISO terms as the preferred terms. When appropriate, alternative terms are included parenthetically to help avoid confusion.

Users of H54-A should understand, however, that the fundamental meanings of the terms are identical in many cases, and to facilitate understanding, terms are defined in the Definitions section of this guideline.

All terms and definitions will be reviewed again for consistency with international use, and revised appropriately during the next scheduled revision of this document.

### **Key Words**

Calibration, certified plasmas, international normalized ratio (INR), international sensitivity index (ISI), prothrombin time (PT), thromboplastin, verification

### **Acknowledgment**

This guideline is being developed through the cooperation of the CLSI Area Committee on Hematology and its Subcommittee on Calibration Plasmas, and Technical Committee C5, Haemostaseology, of the Department for Medical Standards (Normenausschuss Medizin) at the German Standards Institute (Deutsches Institut für Normung [DIN]). Representatives of both CLSI and DIN are participating in the development of each organization's respective standard. It is expected that this effort will advance the international harmonization of this important hematology guideline, thereby improving healthcare delivery worldwide. The DIN representative for this project is Heinz Beeser, MD, PhD, Institute for Quality Management and Standardization in Transfusion Medicine, Teningen, Germany.

## Procedures for Validation of INR and Local Calibration of PT/INR Systems; Approved Guideline

### 1 Scope

CLSI document H54 reviews limitations of the INR system and provides a rationale for performing local PT/INR verification with recommendations as to when calibration may be indicated. The method of certified plasma preparation and method of INR value assignments are described in detail. Also included are the recommended INR range that certified plasmas should cover and recommended number of certified plasmas required for local ISI calibration. A protocol for performing calibration of PT systems is provided. Methods of calculating local ISI are included, as well as the procedure for creating a calibration line in order to interpolate a direct INR.

To facilitate improved precision and accuracy of PT assay results, enhance laboratory standardization, and thereby optimize patient results and care, the guideline has been divided into two parts. Though both may be educational for all users, Part I is primarily intended for manufacturers of the reagents and instruments used in the PT/INR system, and for manufacturers of material such as certified plasmas to standardize the PT assay; Part II is written for laboratory professionals responsible for the performance of prothrombin time (PT) assays.

### 2 Standard Precautions

Because it is often impossible to know what isolates or specimens might be infectious, all patient and laboratory specimens are treated as infectious and handled according to “standard precautions.” Standard precautions are guidelines that combine the major features of “universal precautions and body substance isolation” practices. Standard precautions cover the transmission of all infectious agents and thus are more comprehensive than universal precautions which are intended to apply only to transmission of blood-borne pathogens. Standard and universal precaution guidelines are available from the U.S. Centers for Disease Control and Prevention (Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. *Infect Control Hosp Epidemiol.* 1996;17:53-80). For specific precautions for preventing the laboratory transmission of all infectious agents from laboratory instruments and materials and for recommendations for the management of exposure to all infectious disease, refer to the most current edition of CLSI document M29—*Protection of Laboratory Workers From Occupationally Acquired Infections*.

### 3 Definitions

**accuracy (of measurement)** – closeness of the agreement between the result of a measurement and a true value of the measurand (VIM93)<sup>1</sup>; **NOTE:** See **measurand** and **trueness**, below.

**antivitamin K (AVK) plasma** – plasma from an individual on antivitamin K (AVK) therapy; **NOTE:** See **vitamin K antagonist**, below.

**calibration** – set of operations that establishes, under specified conditions, the relationship between values of quantities indicated by a measuring instrument or measuring system, or values represented by a material measure or a reference material, and the corresponding values realized by standards (VIM93)<sup>1</sup>; **NOTE 1:** According to the U.S. Code of Federal Regulations, calibration is the process of testing and adjustment of an instrument, kit, or test system, to provide a known relationship between the measurement response and the value of the substance being measured by the test procedure (42 CFR § 493)<sup>2</sup>; **NOTE 2:** The term is sometimes used to describe different situations; **NOTE 3:** See **calibration line** and **direct INR determination**, below.